Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of antimicrobial agents for the treatment of experimentally induced infection. Today, animal pharmacokinetic-pharmacodynamic (PK-PD) infection models serve as a cornerstone of the preclinical assessment process for antibacterial agents and dose and dosing interval selection, as decision support for setting in vitro susceptibility breakpoints, and, finally, for the evaluation of the meaning of in vitro resistance. Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models.

[1]  G. Drusano,et al.  Postantibiotic effect of imipenem on Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.

[2]  W. Craig Pharmacodynamics of Antimicrobials: General Concepts and Applications , 2001 .

[3]  H. Eagle,et al.  THE EFFECTIVE CONCENTRATIONS OF PENICILLIN IN VITRO AND IN VIVO FOR STREPTOCOCCI, PNEUMOCOCCI, AND TREPONEMA PALLIDUM , 1950, Journal of bacteriology.

[4]  W. Craig,et al.  Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin , 2002 .

[5]  J. Loutit,et al.  Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia , 2006, Antimicrobial Agents and Chemotherapy.

[6]  M. Dudley,et al.  Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. , 2000, Current opinion in microbiology.

[7]  H. Eagle,et al.  Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels. , 1950, The American journal of medicine.

[8]  G. Drusano,et al.  Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. , 2004, The Journal of infectious diseases.

[9]  Ronald N. Jones,et al.  MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. , 2000, The Journal of antimicrobial chemotherapy.

[10]  R. Owens,et al.  Clinical pharmacodynamics of quinolones. , 2003, Infectious disease clinics of North America.

[11]  Jerome J. Schentag,et al.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. , 1997, The Journal of antimicrobial chemotherapy.

[12]  Ronald N. Jones,et al.  Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Drusano,et al.  Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. , 2005, Diagnostic microbiology and infectious disease.

[14]  E. Ludwig,et al.  Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections , 2004, Antimicrobial Agents and Chemotherapy.

[15]  Thaddeus H. Grasela,et al.  Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections , 2001, Antimicrobial Agents and Chemotherapy.

[16]  B. Cirincione,et al.  Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections , 2007, Antimicrobial Agents and Chemotherapy.

[17]  G. Drusano,et al.  Antimicrobial Pharmacodynamics in Theory and Clinical Practice , 2007 .

[18]  Robert Leary,et al.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.

[19]  G L Drusano,et al.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.

[20]  W. Craig,et al.  In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria , 2000, Antimicrobial Agents and Chemotherapy.

[21]  I. Gould,et al.  The post-antibiotic effect. , 1993, The Journal of antimicrobial chemotherapy.

[22]  V. Lorian Antibiotics in laboratory medicine , 2005 .

[23]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[24]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[25]  Jerome J. Schentag,et al.  Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme , 2003, Clinical pharmacokinetics.

[26]  P. Iversen,et al.  Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection , 2003, Antimicrobial Agents and Chemotherapy.

[27]  G. Woodnutt Pharmacodynamics to combat resistance. , 2000, The Journal of antimicrobial chemotherapy.

[28]  W. Craig,et al.  Killing and regrowth of bacteria in vitro: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[29]  Ronald N. Jones,et al.  Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi , 2005, Antimicrobial Agents and Chemotherapy.

[30]  W. Craig,et al.  In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid) , 2002, Antimicrobial Agents and Chemotherapy.

[31]  H. Eagle,et al.  "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. , 1953, The New England journal of medicine.

[32]  R. Echols The selection of appropriate dosages for intravenous ciprofloxacin. , 1993, Journal of Antimicrobial Chemotherapy.

[33]  M. Basáñez,et al.  Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study , 2004, The Lancet.